Evoke Pharma, EVERSANA, and Omnicell expand GIMOTI access through pharmacy agreements.

Evoke Pharma, a specialty pharmaceutical company, has partnered with Omnicell to expand patient access to GIMOTI, a nasal spray for diabetic gastroparesis, into large gastroenterology organizations. This partnership aims to enhance GIMOTI's reach through key pharmacy relationships, with the addition of Omnicell expected to almost double the Gimoti Specialty Pharmacy Network.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, has announced a strategic partnership with Omnicell (NASDAQ: OMCL) to enhance patient access to GIMOTI®, a nasal spray for acute and recurrent diabetic gastroparesis. The collaboration aims to align GIMOTI with specialty pharmacies used by large gastroenterology group practices, potentially doubling the number of specialty pharmacies available to access Gimoti [1].

Evoke Pharma, in collaboration with EVERSANA, a leading provider of global commercial services to the life sciences industry, has secured access to Omnicell, a leader in medication management and fulfillment. This partnership is expected to expand patient access to GIMOTI into large gastroenterology organizations. The addition of Omnicell is part of Evoke’s strategy to broaden GIMOTI’s reach through key pharmacy partnerships, ensuring better alignment with specialty pharmacies used by large gastroenterology group practices like Gastro Health, which has a presence in 7 states and 150 locations [1].

The partnership with Omnicell is expected to almost double the number of specialty pharmacies available to access Gimoti. This expansion is part of Evoke’s strategy to improve patient access by aligning with the specialty pharmacies that GI physicians trust and use every day. Omnicell manages a collection of these targeted pharmacies that specialize in GI products and are affiliated with large gastrointestinal physician organizations [1].

In addition to the partnership with Omnicell, Evoke has also accessed Brentwood Pharmacy via a partnership agreement via Eversana. Brentwood is the specialty pharmacy affiliated with OneGI, another large gastroenterology network located in Tennessee, Kentucky, Ohio, Mississippi, and other surrounding states. OneGI manages approximately 200 gastroenterologists and specialized physician assistants located at over 30 offices. This expansion further enables rapid delivery of GIMOTI and expands access to additional insurance plans for patients [1].

About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized, and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults [1].

Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents, resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis [1].

Visit www.EvokePharma.com for more information.

Follow Evoke Pharma on LinkedIn
Follow Evoke Pharma on Twitter

References:
[1] https://www.stocktitan.net/news/EVOK/evoke-pharma-and-eversana-expand-gimoti-access-to-gastro-health-and-nl6xvzeomtms.html